Moeini-Naghani I, Hashemi-Zonouz T, Jabbari B. Botulinum toxin treatment of spasticity in adults and children. Semin Neurol. 2016;36(1):64–72.
Koman LA, Paterson Smith B, Balkrishnan R. Spasticity associated with cerebral palsy in children: guidelines for the use of botulinum A toxin. Paediatr Drugs. 2003;5(1):11–23.
Dysport® (abobotulinumtoxinA) for injection: US prescribing information. 2016. https://www.dysport.com. Accessed 3 May 2017.
Keam SJ, Muir VJ, Deeks ED. Botulinum toxin A (Dysport®): in dystonias and focal spasticity. Drugs. 2011;71(8):1043–58.
Thakker MM, Rubin PA. Pharmacology and clinical applications of botulinum toxins A and B. Int Ophthalmol Clin. 2004;44(3):147–63.
Tilton A, Russman B, Aydin R, et al. AbobotulinumtoxinA (Dysport®) improves function according to goal attainment in children with dynamic equinus due to cerebral palsy. J Child Neurol. 2017;32(5):482–7.
Park ES, Sim E, Rha DW. Architectural changes of the gastrocnemius muscle after botulinum toxin Type A injection in children with cerebral palsy. Yonsei Med J. 2014;55:1406–12.
Colovic H, Dimitrijevic L, Stankovic I, et al. The effects of botulinum toxin type A on improvement and dynamic spastic equinus correction in children with cerebral palsy—preliminary results. Arch Med Sci. 2014;10(5):979–84.
Colovic H, Dimitrijevic L, Stankovic I, et al. Estimation of botulinum toxin type A efficacy on spasticity and functional outcome in children with spastic cerebral palsy. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2012;156(1):41–7.
Lee SJ, Sung IY, Jang DH, et al. The effect and complication of botulinum toxin Type A injection with serial casting for the treatment of spastic equinus foot. Ann Rehabil Med. 2011;35(3):344–53.
Bottos M, Benedetti MG, Salucci P, et al. Botulinum toxin with and without casting in ambulant children with spastic diplegia: a clinical and functional assessment. Dev Med Child Neurol. 2003;45(11):758–62.
Hesse S, Brandl-Hesse B, Seidel U, et al. Lower limb muscle activity in ambulatory children with cerebral palsy before and after the treatment with Botulinum toxin A. Restor Neurol Neurosci. 2000;17(1):1–8.
Fazzi E, Maraucci I, Torrielli S, et al. Factors predicting the efficacy of botulinum toxin-A treatment of the lower limb in children with cerebral palsy. J Child Neurol. 2005;20(8):661–6.
Metaxiotis D, Siebel A, Doederlein L. Repeated botulinum toxin A injections in the treatment of spastic equinus foot. Clin Orthop Relat Res. 2002;394:177–85.
Heinen F, Wissel J, Philipsen A, et al. Interventional neuropediatrics: treatment of dystonic and spastic muscular hyperactivity with botulinum toxin A. Neuropediatrics. 1997;28(6):307–13.
Frasson E, Dall’ora E, Bordignon M, et al. Spread of botulinum neurotoxin Type A at standard doses is inherent to the successful treatment of spastic equinus foot in cerebral palsy: short-term neurophysiological and clinical study. J Child Neurol. 2012;27(5):587–93.
Geva-Dayan K, Domenievitz D, Zahalka R, et al. Botulinum toxin injections for pediatric patients with hereditary spastic paraparesis. J Child Neurol. 2010;25(8):969–75.
Unlu E, Cevikol A, Bal B, et al. Multilevel botulinum toxin Type A as a treatment for spasticity in children with cerebral palsy: a retrospective study. Clinics. 2010;65(6):613–9.
Sätilä HK, Pietikainen T, Lehtonen-Raty P, et al. Treatment of spastic equinus gait with botulinum toxin A: does dose matter? Analysis of a clinical cohort. Neuropediatrics. 2006;37(6):344–9.
Dabrowski E, Bonikowski M, Gormley M, et al. Efficacy and safety of abobotulinumtoxinA (Dysport®) in children with dynamic equinus foot deformity previously treated with botulinum toxins. In: Annual meeting of the association of academic physiatrists. 2017.
Delgado MR, Russman B, Gormley M, et al. Effect of abobotulinumtoxinA (Dysport®) injections on functioning in children with dynamic equinus foot deformity due to cerebral palsy: analysis of treatment goals, gait and quality of life from a phase 3 study [abstract]. Am J Phys Med Rehabil. 2016;95(Suppl 3):a5.
Delgado MR, Tilton A, Russman B, et al. AbobotulinumtoxinA for equinus foot deformity in cerebral palsy: a randomized controlled trial. Pediatrics. 2016;137(2):e20152830.
Tse A, Tilton A, Bonikowski M, et al. Goal selection using the Goal Attainment Scale in ambulatory patients with cerebral palsy according to GMFSC levels in a randomized, double-blind placebo-controlled study of abobotulinumtoxina (Dysport®) [abstract no. SP15]. Dev Med Child Neurol. 2014;56(Suppl 5):11.
Bonikowski M, Tilton A, Gormley M, et al. Abobotulinumtoxin A in children with lower limb spasticity due to cerebral palsy: safety and efficacy results of a phase III open-label extension study [abstract no. P78]. Gait Posture. 2016;49(Suppl 2):222.
Baker R, Jasinski M, Maciag-Tymecka I, et al. Botulinum toxin treatment of spasticity in diplegic cerebral palsy: a randomized, double-blind, placebo-controlled, dose-ranging study. Dev Med Child Neurol. 2002;44(10):666–75.
Ubhi T, Bhakta BB, Ives HL, et al. Randomised double blind placebo controlled trial of the effect of botulinum toxin on walking in cerebral palsy. Arch Dis Child. 2000;83(6):481–7.
Kanovsky P, Bares M, Severa S, et al. Long-term efficacy and tolerability of 4-monthly versus yearly botulinum toxin Type A treatment for lower-limb spasticity in children with cerebral palsy. Dev Med Child Neurol. 2009;51(6):436–45.
Moore AP, Ade-Hall RA, Smith CT, et al. Two-year placebo-controlled trial of botulinum toxin A for leg spasticity in cerebral palsy. Neurology. 2008;71(2):122–8.
Mall V, Heinen F, Siebel A, et al. Treatment of adductor spasticity with BTX-A in children with CP: a randomized, double-blind, placebo-controlled study. Dev Med Child Neurol. 2006;48(1):10–3.
Matthews D, Camba GC, Pascual-Pascual I, et al. Safety and tolerability of abobotulinumtoxina (Dysport®) in children (2–17 years) with lower limb spasticity due to cerebral palsy: a pooled analysis of 8 clinical trials [poster 485]. PM R. 2016;8(9):S318.
Dabrowski D, Bonikowski M, Gormley M, et al. Efficacy and safety of abobotulinumtoxinA (Dysport®) in children with dynamic equinus foot deformity previously treated with botulinum toxins [abstract no. 126]. Ann Neurol. 2016;80(Suppl 2):S368.
Delgado MR, Hirtz D, Aisen M, et al. Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2010;74(4):336–43.